Journal article icon

Journal article

Pharmacodynamic and pharmacokinetic markers for anti-angiogenic cancer therapy: Implications for dosing and selection of patients.

Abstract:

Angiogenesis is integral to tumour growth and invasion, and is a key target for cancer therapeutics. However, for many of the licensed indications, only a modest clinical benefit has been observed for both monoclonal antibody and small-molecule tyrosine kinase inhibitor anti-angiogenic therapy. Pre-clinical and clinical studies have attempted to evaluate circulating, imaging, genomic, pharmacokinetic, and pharmacodynamic markers that may aid both the selection of patients for treatment and de...

Expand abstract
Publication status:
Published
Peer review status:
Reviewed (other)

Actions


Access Document


Publisher copy:
10.1007/s13318-017-0442-x

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
RDM; Weatherall Insti. of Molecular Medicine
Role:
Author
ORCID:
0000-0002-1790-1185
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Oxford college:
St Hugh's College
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Oncology
Role:
Author
Breast Cancer Research Foundation More from this funder
Fondazione Umberto Veronesi More from this funder
Cancer Research UK More from this funder
Publisher:
Springer Publisher's website
Journal:
European Journal of Drug Metabolism and Pharmacokinetics Journal website
Publication date:
2017-10-01
DOI:
EISSN:
2107-0180
ISSN:
0378-7966
Pmid:
29019020
Source identifiers:
735455
Language:
English
Keywords:
Pubs id:
pubs:735455
UUID:
uuid:c741b8dd-2eaf-45e4-8859-25dcfba295de
Local pid:
pubs:735455
Deposit date:
2018-01-23

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP